Polyarteritis nodosa epidemiology and demographics
|
Polyarteritis nodosa Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polyarteritis nodosa epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polyarteritis nodosa epidemiology and demographics |
|
Polyarteritis nodosa epidemiology and demographics in the news |
|
Risk calculators and risk factors for Polyarteritis nodosa epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Sargun Singh Walia M.B.B.S.[3]
Overview
The incidence of polyarteritis nodosa is approximately 3 to 4 per 100,000 individuals worldwide.The prevalence among alaskan population suffering with hepatitis B infection is approximately 7.7 per 100,000 individuals.Patients of all age groups may develop polyarteritis nodosa.There is no racial predilection to polyarteritis nodosa.Males are more commonly affected by polyarteritis nodosa than females.Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries.
Epidemiology and Demographics
Incidence
Prevalence
- The prevalence among alaskan population suffering with hepatitis B infection is approximately 7.7 per 100,000 individuals.
Age
- Patients of all age groups may develop polyarteritis nodosa.
- Polyarteritis nodosa is mostly diagnosed in patients aged 45-65 years. [2]
Race
- There is no racial predilection to polyarteritis nodosa.
Gender
- Males are more commonly affected by polyarteritis nodosa than females. The male to female ratio is approximately 1.5 to 1.
Region
- Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries. [3]
- The annual incidence in three regions of Europe was estimated to be 4.4 to 9.7 per million [4].
References
- ↑ McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP (January 1989). "Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up". Hepatology. 9 (1): 97–101. PMID 2562798.
- ↑ Colmegna I, Maldonado-Cocco JA (August 2005). "Polyarteritis nodosa revisited". Curr Rheumatol Rep. 7 (4): 288–96. PMID 16045832.
- ↑ Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden". Rheumatology (Oxford). 46 (8): 1329–37. doi:10.1093/rheumatology/kem107. PMID 17553910.
- ↑ Watts RA, Lane SE, Bentham G, Scott DG (2000). "Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom". Arthritis Rheum. 43 (2): 414–9. doi:10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0. PMID 10693883.